PAT rose 109% YoY to ₹937m and adjusted EPS was ₹8.2.

_Consolidated · Q2 FY27_ EBITDA rose 53% YoY to ₹1,633m and EBITDA margin expanded 329 bps YoY to 31.6%, which the company attributes to operating leverage from higher volumes across the business. The company signed a US partner for integrated drug substance and drug product across multiple programs in Biologics during the quarter. 🔬 Q2FY27 saw 12 new launches across North America, MENA and LatAm and 6 new wins, including 2 in Biologics, the company says. The company completed 11 regulatory inspections and customer audits during the quarter and received DRL approval across LatAm, Africa, the Middle East, Canada and India. Significant margin expansion (31.6%, +329 bps YoY) signals operating leverage as volumes rise — a key validation of the company's capacity investments. Commercialisation of DDC cartridge line 2 (and line 3 FAT complete) materially increases sterile/ device capacity — enables indexed revenue ramp from new launches and wins. US partner for integrated biologics programs expands addressable market into higher-value biologics CDMO work, which can lift long‑term ASPs and margins if wins convert to scale.